Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Absolute Bioavailability of Seltorexant in Healthy Participants
NCT05236868Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2022
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of seltorexant in major depressive disorder (MDD) and Insomnia, sponsored by Janssen Pharmaceutical. Primary endpoint: Absolute Bioavailability. Started Feb 2022; status: completed.
02
Drugs
seltorexant
03
Conditions
major depressive disorder (MDD)Insomnia
Beyond the preview
Go deeper on NCT05236868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05236868.